University of Massachusetts Medical Center
The Hepatitis C virus infects nearly 170 million people worldwide, and is the major cause of hepatitis and liver cancer. The current treatment is a therapy with pegylated interferon and ribavirin, which has severe side effects. Recent addition of HCV NS3/4A protease inhibitors to this therapy has improved HCV treatments, but the severe side effects and rapid emergence of drug resistance limit the effectiveness of this therapy. Therefore, new HCV therapies must be developed that are effective against a broader spectrum of resistant viral variants and HCV genotypes. This project followed the multi-step synthesis of a new variant of the MK-5172 inhibitor, evaluated the synthesis plan, and provided the UMass Medical School with a new inhibitor to test activity against NS3/4A protease variants.
Worcester Polytechnic Institute
Major Qualifying Project
All authors have granted to WPI a nonexclusive royalty-free license to distribute copies of the work, subject to other agreements. Copyright is held by the author or authors, with all rights reserved, unless otherwise noted.
Chemistry and Biochemistry
Your accessibility may vary due to other restrictions.